Efficacy and Safety of Lebrikizumab in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial (ADhere)

IMPORTANCE: Lebrikizumab (LEB), a high-affinity monoclonal antibody targeting interleukin (IL)-13, demonstrated efficacy and safety in patients with moderate-to-severe atopic dermatitis (AD) during 16 weeks of monotherapy in a phase 2b trial, and two 52-week phase 3 trials. OBJECTIVE: To evaluate ef...

Descripción completa

Detalles Bibliográficos
Autores principales: Simpson, Eric L., Gooderham, Melinda, Wollenberg, Andreas, Weidinger, Stephan, Armstrong, April, Soung, Jennifer, Ferrucci, Silvia, Lima, Renata Gontijo, Witte, Michael M., Xu, Wen, ElMaraghy, Hany, Natalie, Chitra R., Pierce, Evangeline, Blauvelt, Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2023
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9857439/
https://www.ncbi.nlm.nih.gov/pubmed/36630140
http://dx.doi.org/10.1001/jamadermatol.2022.5534

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9857439/
https://www.ncbi.nlm.nih.gov/pubmed/36630140
http://dx.doi.org/10.1001/jamadermatol.2022.5534

Ejemplares similares